Taskin, OSadik, SOnoglu, AGokdeniz, RErturan, EBurak, FWheeler, JM2024-08-042024-08-0420001074-3804https://doi.org/10.1016/S1074-3804(05)60478-1https://hdl.handle.net/11616/93267Study Objectives. To evaluate long-term effects of operative hysteroscopy on the development of intrauterine adhesions (IUA), and to determine whether hypoestrogenism has a modulatory role in preventing IUA. Design. Prospective, randomized study (Canadian Task Force classification I). Setting. Tertiary-care teaching hospital. Patients. Ninety-five women requiring resectoscopic surgery. Intervention. Hysteroscopic surgery using the resectoscope and 1.5% glycine for uterine distention. Measurements and Main Results. indications for hysteroscopy were polyps (28 patients), solitary myoma (32), multiple myomata (20), and uterine septa (15). Patients in each group were randomized to endometrial suppression with danazol or placebo. Second-look office hysteroscopy with CO2 for uterine distention was performed after the First menses after surgery to assess the frequency, extent, and severity of IUA. The likelihood and severity of IUA depended on the pathology treated at initial surgery. Of women treated For polyps and uterine septa, in only one with septa (placebo group) developed IUA. Mild IUA Formation was present in 10 patients (31.3%) with solitary fibroids and 9 (45.5%) with multiple myomata. The frequency was similar in placebo- and danazol-treated groups with both solitary and multiple myomas (50% and 44.4% vs 50% and 55.6%). All IUA were lysed during second-look surgery except in one woman with multiple myomata who required repeat resectoscopy. Conclusion. Intrauterine adhesions are the major long-tern, complication of operative hysteroscopy, with frequency dependent on the pad,ology initially treated. Second-look office hysteroscopy is a cost-effective method of diagnosing and lysing IUA after resectoscopy.eninfo:eu-repo/semantics/closedAccessHysteroscopic SurgeryGnrh AgonistOfficeArticle733513541092462910.1016/S1074-3804(05)60478-12-s2.0-0034435809N/AWOS:000167072800009Q2